{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:37:32Z","timestamp":1790498252506,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":1198,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1111\/jth.14491","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T04:08:57Z","timestamp":1558670937000},"page":"1470-1477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program"],"prefix":"10.1016","volume":"17","author":[{"given":"Gallia G.","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Asikanius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kuebler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Benchikh El Fegoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sille","family":"Esbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Seremetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14491_bb0010","unstructured":"FDA. Highlights of prescribing information \u2010 NovoSeven\u00ae RT, Coagulation Factor VIIa (Recombinant). Available at https:\/\/wwwfdagov\/downloads\/\/ucm056954pdf. 2014; Accessed 14 Sep 2018."},{"key":"10.1111\/jth.14491_bb0015","unstructured":"EMA. NovoSeven summary of product characteristics. Available at http:\/\/wwwemaeuropaeu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000074\/WC500030873pdf. 2016; Accessed 14 Sep 2018."},{"key":"10.1111\/jth.14491_bb0020","unstructured":"EMA. Summary of product characteristics \u2010 Hemlibra. Available at http:\/\/wwwemaeuropaeu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004406\/WC500244743pdf. 2018; Accessed 14 Sep 2018."},{"key":"10.1111\/jth.14491_bb0025","first-page":"11","article-title":"In vitro thrombin generation testing and in vivo venous stasis model for assessing the pro\u2010coagulant effects of FVIII, emicizumab, rFVIIa, and aPCC","volume":"23","author":"Adamkewicz","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14491_bb0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.thromres.2009.11.027","article-title":"Recombinant coagulation factor VIIa\u2013from molecular to clinical aspects of a versatile haemostatic agent","volume":"125","author":"Persson","year":"2010","journal-title":"Thromb Res"},{"issue":"suppl 1","key":"10.1111\/jth.14491_bb0035","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0268-960X(15)30006-0","article-title":"Safety update on the use of recombinant activated factor VII in approved indications","volume":"29","author":"Neufeld","year":"2015","journal-title":"Blood Rev"},{"key":"10.1111\/jth.14491_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14491_bb0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2018-99-118153","article-title":"Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia \u0391 with inhibitors: results from the HAVEN 2 study","volume":"132","author":"Young","year":"2018","journal-title":"Blood"},{"key":"10.1111\/jth.14491_bb0050","first-page":"209","article-title":"Emicizumab subcutaneous dosing every 4\u00a0weeks is safe and efficacious in the control of bleeding in persons with hemophilia A (PwHA) with and without inhibitors: results from Phase 3 HAVEN 4 study","volume":"24","author":"Pipe","year":"2018","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14491_bb0055","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1111\/jth.14491_bb0060","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/00001721-200004001-00010","article-title":"Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII","volume":"11","author":"Lusher","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14491_bb0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2516.2010.02265.x","article-title":"The need for speed in the management of haemophilia patients with inhibitors","volume":"17","author":"Salek","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14491_bb0070","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14491_bb0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2516.2008.01837.x","article-title":"Clinical outcome of moderate haemophilia compared with severe and mild haemophilia","volume":"15","author":"den Uijl","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14491_bb0080","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/hae.12329","article-title":"Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 mug kg(\u2010)(1)) rFVIIa doses across clinical trials and registries","volume":"20","author":"Shapiro","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14491_bb0085","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1538-7836.2004.00759.x","article-title":"Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors","volume":"2","author":"Abshire","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14491_bb0090","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2516.2008.01829.x","article-title":"Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors","volume":"14","author":"Abshire","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14491_bb0095","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1055\/s-0037-1608943","article-title":"Real\u2010world early treatment with room temperature\u2013stable recombinant factor VIIa in hemophilia A\/B and inhibitors: SMART\u20107\u2122 post hoc analyses","volume":"01","author":"Demartis","year":"2017","journal-title":"TH Open"},{"key":"10.1111\/jth.14491_bb0100","unstructured":"NHF. MASAC Update on the Approval and Availability of the New Treatment: Emicizumab (Hemlibra), for Persons with Hemophilia A with Inhibitors to Factor VIII: Interim Guidance on Acute Bleed Management and Use of Laboratory Assays. Available at https:\/\/wwwhemophiliaorg\/sites\/default\/files\/MASAC-Update-on-the-Approval-and-Availability-of-the-New-Treatmentpdf. 2017; Accessed: 19 Sep 2018."},{"key":"10.1111\/jth.14491_bb0105","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"Collins","year":"2018","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622141395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622141395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:14:35Z","timestamp":1761534875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622141395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1538783622141395"],"URL":"https:\/\/doi.org\/10.1111\/jth.14491","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 F. Hoffman La-Roche AG. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}